HBIO Harvard Bioscience Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HBIO

Price (delayed)

$8

Market cap

$36.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.31

Enterprise value

$72.52M

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 39
Relative Profitability: Rel. Profitability: 40

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production ...

Highlights
Harvard Bioscience's revenue has increased by 2.7% from the previous quarter
The gross profit has grown by 2.2% since the previous quarter
HBIO's quick ratio has soared by 143% YoY but it is down by 7% QoQ
The EPS has soared by 82% YoY but it has contracted by 5% from the previous quarter
The equity has dropped by 53% year-on-year and by 26% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.harvardbioscience.com
Peers: BRKR A TMO JNJ

Key stats

What are the main financial stats of HBIO

HBIO stock price

How has the Harvard Bioscience stock price performed over time
Intraday
-2.44%
1 week
1.27%
1 month
26.78%
1 year
68.78%
YTD
19.58%
QTD
30.08%

Financial performance

How have Harvard Bioscience's revenue and profit performed over time
Revenue
$87.81M
Gross profit
$51.07M
Operating income
-$245,000
Net income
-$10.41M
Gross margin
58.2%
Net margin
-11.9%
Harvard Bioscience's operating margin has plunged by 200% from the previous quarter but it has soared by 99% YoY
HBIO's operating income has dropped by 185% since the previous quarter but it has surged by 100% year-on-year
Harvard Bioscience's net margin has soared by 82% YoY but it has decreased by 4.4% from the previous quarter
The company's net income has surged by 82% YoY but it fell by 6% QoQ

Price vs fundamentals

How does HBIO's price correlate with its fundamentals

Growth

What is Harvard Bioscience's growth rate over time

Valuation

What is Harvard Bioscience stock price valuation
P/E
N/A
P/B
4.86
P/S
0.41
EV/EBIT
N/A
EV/EBITDA
42.59
EV/Sales
0.83
The EPS has soared by 82% YoY but it has contracted by 5% from the previous quarter
HBIO's price to book (P/B) is 111% more than its 5-year quarterly average of 2.3 and 103% more than its last 4 quarters average of 2.4
The equity has dropped by 53% year-on-year and by 26% since the previous quarter
The stock's price to sales (P/S) is 66% less than its 5-year quarterly average of 1.2 but 37% more than its last 4 quarters average of 0.3
Harvard Bioscience's revenue has increased by 2.7% from the previous quarter

Efficiency

How efficient is Harvard Bioscience business performance
HBIO's return on invested capital has surged by 94% year-on-year and by 15% since the previous quarter
The ROS has soared by 93% YoY and by 7% from the previous quarter
The return on assets has surged by 76% year-on-year but it has declined by 7% since the previous quarter
The return on equity has grown by 36% year-on-year but it has declined by 26% since the previous quarter

Dividends

What is HBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HBIO.

Financial health

How did Harvard Bioscience financials performed over time
The total assets is 11% more than the total liabilities
HBIO's quick ratio has soared by 143% YoY but it is down by 7% QoQ
HBIO's current ratio has surged by 131% year-on-year but it is down by 6% since the previous quarter
The company's debt to equity has surged by 116% YoY and by 35% QoQ
The equity has dropped by 53% year-on-year and by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.